TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33455926
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside (IIM) 20 mg/kg
Study: 35989346
Drug: Diltiazem 30
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 30 mg every 12 hours
Study: 34125135
Drug: Brief cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief cessation advice, a 1-week free sample of nicotine replacement therapy (NRT), and active referral to a community-based smoking cessation service.
Study: 36279236
Drug: Neodolpasse (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodolpasse (30 mg Orphenadrine and 75 mg Diclofenac)
Study: 36279236
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with Morphine
Study: 36279236
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with Morphine
Study: 32727835
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 600 mg
Study: 32727835
Drug: Control (interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (interferon beta or no disease-modifying therapy)
Study: 39294486
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles
Study: 34894702
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration (PAI) with 100 mL cocktail solution (ropivacaine 20 mL, ketorolac 2 mL, epinephrine 1 mL mixed with normal saline)
Study: 34894702
Drug: Pericapsular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericapsular nerve group (PENG) block with 30 mL of 0.5% ropivacaine
Study: 34118411
Drug: Continuous processing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous processing of milled drug‐loaded electrospun materials to tablet form
Study: 35938130
Drug: Mg +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg + B vitamins + green tea + rhodiola
Study: 33896388
Drug: Mg +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg + B vitamins + rhodiola
Study: 33896388
Drug: Mg +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg + B vitamins + green tea
Study: 32174625
Drug: Customized oral
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized oral health educational video (Group A)
Study: 32419038
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy strategies
Study: 35293844
Drug: Select exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Select exercise modalities (e.g. treadmill exercise)
Study: 34349379
Drug: Fentanyl patch
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl patch 25 μg·h‐1
Study: 34349379
Drug: Buprenorphine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine patch 10 μg·h‐1
Study: 34349379
Drug: Buprenorphine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine patch 20 μg·h‐1
Study: 32028395
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment
Study: 35179742
Drug: Independent predictors
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent predictors of NRF: age ≥ 65 years (OR: 2.473, p < 0.01), heart rate ≥ 89 bpm (OR: 1.622, p < 0.05), Killip class ≥ II (OR: 1.914, p < 0.01), total ischemic time ≥ 268 min (OR: 2.652, p < 0.01), thrombus burden G≥4 (OR: 8.351, p < 0.01)
Study: 34009291
Drug: Perioperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative systemic therapy (CAPOX, FOLFOX, or FOLFIRI)
Study: 36001429
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (intravenous clamping procedure to achieve a breath alcohol concentration of 0.05% maintained over 3 hours)
Study: 36001429
Drug: Self-administered alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered alcohol (intravenous)
Study: 34463420
Drug: Dulaglutide 3.0
Normalized name: Dulaglutide 3.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [Trulicity]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 3.0 mg and 4.5 mg
Study: 37097308
Drug: Telerehabilitation exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation exercise program (clinical Pilates-based exercises via YouTube, performed twice daily for 8 weeks)
Study: 37264734
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg once daily
Study: 35373340
Drug: Subgingival air-polishing
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival air-polishing therapy with erythritol powder (EPAP) as adjunct to conventional subgingival instrumentation
Study: 34672254
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of terazosin hydrochloride (2 mg)
Study: 34672254
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of terazosin hydrochloride (2 mg)
Study: 34069308
Drug: Meal kit
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal kit provision (6 weekly kits, 3 meals per kit)
Study: 33226524
Drug: darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darolutamide 600 mg twice daily
Study: 36243580
Drug: HYR-PB21 300
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HYR-PB21 300 mg
Study: 36243580
Drug: HYR-PB21 150
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HYR-PB21 150 mg
Study: 36243580
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 75 mg
Study: 33822406
Drug: CT‐P17 AI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐P17 AI (40 mg/0.4 mL)
Study: 33822406
Drug: CT‐P17 PFS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐P17 PFS (40 mg/0.4 mL)
Study: 33730255
Drug: Received treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received treatment for HCV
Study: 33524293
Drug: Rifaximin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (600 mg twice daily)
Study: 33136048
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by implants with 2 Locator attachments
Study: 33262577
Drug: Escitalopram oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram oxalate 20 mg tablets (generic)
Study: 34031262
Drug: Tight-Step-Up (TSU)
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tight-Step-Up (TSU) (MTX without oral GCs)
Study: 34031262
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of total NSAID and analgesic use
Study: 34031262
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of chronic NSAID and analgesic use
Study: 34031262
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of daily chronic NSAID use
Study: 33026143
Drug: efpeglenatide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: efpeglenatide (4 mg or 6 mg)
Study: 33189178
Drug: Selinexor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (100 mg once per week), bortezomib (1.3 mg/m2 once per week), and dexamethasone (20 mg twice per week)
Study: 33189178
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2 twice per week for the first 24 weeks and once per week thereafter) and dexamethasone (20 mg four times per week for the first 24 weeks and twice per week thereafter)
Study: 38320511
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg twice daily)
Study: 33338442
Drug: sequential FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential FOLFIRINOX
Study: 33964325
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of androgen deprivation therapy (ADT) plus high-dose radiotherapy (HRT)
Study: 32294560
Drug: Lidocaine 7%
Normalized name: LIDOCAINE 7%/TETRACAINE 7% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 7% and Tetracaine 7% self-occlusive cream (LT-C), applied 1 hour before MAL-cPDT session.
Study: 32294560
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (control group).
Study: 32294560
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of LT-C vs Vehicle cream.
Study: 36371994
Drug: Trastuzumab-plus-chemotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-plus-chemotherapy group (n = 36)
Study: 36371994
Drug: Trastuzumab-monotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-monotherapy group (n = 52)
Study: 32183768
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy (EYT) and Tai Chi
Study: 38522443
Drug: Low-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow oxygen therapy
Study: 33245905
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEI) therapy
Study: 33245905
Drug: Target dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dosing of beta-blocker and ACEI therapy
Study: 32819445
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (IV-TXA 15 mg/kg + local TXA 2 g)
Study: 32819445
Drug: IV group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV group (IV-TXA 15 mg/kg)
Study: 32819445
Drug: Topical group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical group (local TXA 2 g)
Study: 32819445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mL IV)
Study: 33048875
Drug: Combination prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination prevention intervention with universal ART (Arm A)
Study: 32773450
Drug: Myostatin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myostatin inhibitors
Study: 35347399
Drug: Balneological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneological treatment (peloidotherapy + hydrotherapy)
Study: 35347399
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (balneological treatment and control)
Study: 33971731
Drug: Services from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Services from a similar team that includes a nurse care coordinator for medication management support and medical care
Study: 35629233
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg after anesthetic induction)
Study: 32335950
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg oestradiol benzoate (0EB group; n=12)
Study: 32335950
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oestradiol benzoate (0.5EB group; n=12)
Study: 32335950
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg oestradiol benzoate (1.0EB group; n=12)
Study: 32828837
Drug: Trials with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials with non-significant difference between treatments for primary outcome
Study: 34530594
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Study: 32770831
Drug: CBDV (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBDV (400 mg/day)
Study: 33420287
Drug: Reduced-dose posttransplant
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose posttransplant cyclophosphamide (20 mg/kg for MSD-PTCy cohort, 25 mg/kg for haplo-PTCy cohort) on days +3, +4 combined with cotransplantation of peripheral blood stem cells (PBSCs) and human umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Study: 33420287
Drug: Reduced-dose posttransplant
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose posttransplant cyclophosphamide (20 mg/kg for MSD-PTCy cohort, 25 mg/kg for haplo-PTCy cohort) on days +3, +4 combined with cotransplantation of PBSCs and UC-MSCs
Study: 36444391
Drug: CHECC‐uP intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHECC‐uP intervention (cervical cancer brochure plus 30-60 min health literacy-focused education followed by monthly phone counselling and navigation assistance for 6 months)
Study: 34029521
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU 4 times per day for 8 weeks)
Study: 36058058
Drug: 1.5 kcal/ml
Normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 kcal/ml enteral formula
Study: 36058058
Drug: 1.0 kcal/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 kcal/ml enteral formula
Study: 34154344
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) combined with transcranial direct current stimulation (tDCS)
Study: 32020044
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with lenalidomide (20 mg/day for days 1-21)
Study: 32020044
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy without lenalidomide
Study: 32020044
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with lenalidomide
Study: 33596722
Drug: Cyproheptadine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (8 mg, competitive 5-HT2 antagonist)
Study: 35422427
Drug: TD139 (0.3-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD139 (0.3-10 mg once daily for 14 days)
Study: 35422427
Drug: TD139 (0.15-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD139 (0.15-50 mg single doses)
Study: 34599040
Drug: Octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide acetate (low, medium, and high doses)
Study: 32114729
Drug: rhGM‐CSF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF gel (10 mg per square centimeter, dressing change every 24 hours until complete healing)
Study: 32114729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (aloe vera gel, same treatment protocol)
Study: 34059974
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied before implant bed preparation and after suturing (808-nm GaAlA laser, 80 seconds; 11J/cm2)
Study: 33139757
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g of maltodextrin)
Study: 33454232
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil inhalation (3 drops of 1.5% for 30 nights)
Study: 33454232
Drug: Chamomile essential
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile essential oil inhalation (3 drops of 1.5% for 30 nights)
Study: 33454232
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhalation of distilled water for 30 nights)
Study: 36414783
Drug: One-shot cognitive
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-shot cognitive behavioral therapy for insomnia (CBT-I)
Study: 32960536
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (AT; prophylactic antibiotics and steroids)
Study: 32960536
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (AT-free group)
Study: 32960536
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (AT)
Study: 36281094
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous fluid loading with Ringer's lactate solution
Study: 33638801
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg subcutaneously injected once before revascularization + 14 days after the first dose)
Study: 33638801
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no evolocumab injection)
Study: 33314799
Drug: Mock laser
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock laser acupuncture (ML)
Study: 32541773
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (iNO) 160 ppm plus oxygen/air for 30 min, five times/day, up to 5 days
Study: 32096884
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure intervention
Study: 34883305
Drug: Blueberry intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry intake (26 g freeze-dried blueberries)
Study: 34883305
Drug: Placebo (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (26 g isocaloric matched placebo)
Study: 37170922
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg subcutaneously every 2 weeks
Study: 35717166
Drug: MTV calculated
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTV calculated using SUV140%L threshold
Study: 35717166
Drug: TLG calculated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLG calculated using SUV140%L threshold
Study: 34085953
Drug: Hypoglycemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (plasma glucose < 3.0 mmol/L)
Study: 33724883
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily of canagliflozin
Study: 34879449
Drug: Dupilumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing >30 kg)
Study: 33606918
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg
Study: 33267925
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS (7.5 mL of 2.5 mg/mL, equivalent to 18.8 mg of amphetamine base)
Study: 33267925
Drug: ER MAS
Normalized name: E-Z Spacer Mask
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER MAS (30 mg capsule, equivalent to 18.8 mg of amphetamine base)
Study: 33341413
Drug: DISCO intervention
Normalized name: DISC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISCO intervention group (systematic follow‐up by a dietitian to adhere to the Dietary Approaches to Stop Hypertension nutrition model together with optimal medical therapy [OMT])
Study: 32805740
Drug: n-3 LC-PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LC-PUFAs (1 g of fish oil 3 times a day for 2 months containing 360 mg EPA and 240 mg DHA)
Study: 32707001
Drug: MRG-110 (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRG-110 (0.01 to 1.5 mg/kg body weight)
Study: 32707001
Drug: MRG-110 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRG-110 (1.5 mg/kg)
Study: 35767935
Drug: Topical aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aloe vera gel
Study: 35263681
Drug: holoBLG lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: holoBLG lozenge
Study: 32745734
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/d) plus Clopidogrel (75 mg/d) for 6 months followed by random assignment to aspirin plus clopidogrel for an additional 6 months
Study: 32745734
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/d) plus Placebo for an additional 6 months
Study: 32745734
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d) plus Placebo for an additional 6 months
Study: 35710395
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training with post-exercise sauna treatments (ET + S, n = 8)
Study: 35710395
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training without sauna treatments (ET, n = 7)
Study: 35598636
Drug: Multi-component edetate
Normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component edetate disodium (Na2EDTA)‐based chelation solution, 40 weekly infusions
Study: 35598636
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral, high-dose multivitamin and mineral supplements
Study: 35598636
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group for chelation therapy)
Study: 35598636
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group for multivitamin and mineral supplements)